Interesting Cases in Surgical Pathology a Malignant Neoplasm in the Brain
Total Page:16
File Type:pdf, Size:1020Kb
Interesting cases in surgical pathology A malignant neoplasm in the brain Ashley Cimino‐Mathews, MD Assistant Professor of Pathology and Oncology The Johns Hopkins Hospital 24 March 2013 Case Presentation A 54 year‐old female presented to the emergency department with mental status changes and was found to have a large dural‐ based brain mass. The patient had a reported history of melanoma and breast cancer (ER 1%, PR‐, Her2‐). The patient underwent resection of the brain tumor. Brain lesion Brain lesion Brain lesion Brain lesion Brain lesion Brain lesion: Sox10 Positive Brain lesion: GATA3 negative (lymphocytes are positive internal control) Is this a metastatic melanoma? Metastatic melanoma? • Diffuse Sox10 immunoreactivity is typically used to support a diagnosis of melanoma or a nerve sheath tumor. • The morphology of this brain lesion in keeping with malignant melanoma. However…diffuse Sox10 immunoreactivity has also been documented in other neoplasms: primary brain tumors (most often astrocytomas), salivary gland neoplasms, and breast carcinoma. The patient’s prior lumpectomy slides were retrieved and additional immunostains performed Breast tumor Breast tumor Breast tumor Breast tumor: CK7 positive Breast tumor: HMB45 negative Breast tumor: Sox10 positive Additional immunostains were performed on the brain lesion Brain lesion Brain lesion: CK7 positive Brain lesion: ER focally positive Final diagnosis: Metastatic breast carcinoma to the brain Case lessons learned 1. Sox10 can be expressed in primary breast carcinomas, primarily triple‐negative carcinomas 2. Sox10 can be expressed in metastatic breast carcinomas – Potential diagnostic utility as triple negative breast carcinomas may not label for traditional markers of mammary differentiation 3. Sox10 labeling in breast carcinomas is a potential diagnostic pitfall for metastatic melanoma Case lessons learned 1. Sox10 can be expressed in primary breast carcinomas, primarily basal‐like carcinomas 2. Sox10 can be expressed in metastatic breast carcinomas – Potential diagnostic utility as triple negative breast carcinomas may not label for traditional markers of mammary differentiation 3. Sox10 labeling in breast carcinomas is a potential diagnostic pitfall for metastatic melanoma What is Sox10? What is Sox10? • Sox10 is a transcription factor in the Sox (Sry‐related HMG box) gene family, which have HMG DNA‐binding domains and play a role in many developmental processes including the development of the immune, nervous and skeletal systems. • Sox10 has a role in the survival, maturation and differentiation of neural‐crest derived melanocytes and glial cells. • In the breast, Sox10 is required for Notch4‐PBP mediated cell growth of mammary epithelial cells in in vitro mouse models. Sox10 Immunohistochemistry: initial utility in neural‐crest derived tissues • Normal tissues that demonstrated Sox10+ labeling: – Schwann cells, melanocytes and the myoepithelial cells of the salivary glands, bronchial mucosa, and breast. • Neoplastic tissues that demonstrated Sox10+ labeling: – 97% of melanomas, 100% of schwannomas and neurofibromas, 100% of salivary gland myoepitheliomas, as well as a subset of malignant peripheral nerve sheath tumors, paragangliomas, carcinoids and astrocytomas. • In this study, none of the 25 epithelial tumors (including 8 breast carcinomas) labeled for Sox10. Nonaka D, et al. Am J Surg Pathol. 2008;32:1291‐1298. Sox10 Immunohistochemistry: initial utility in neural‐crest derived tissues • Normal tissues that demonstrated Sox10+ labeling: – Schwann cells, melanocytes and the myoepithelial cells of the salivary glands, bronchial mucosa, and breast. • Neoplastic tissues that demonstrated Sox10+ labeling: – 97% of melanomas, 100% of schwannomas and neurofibromas, 100% of salivary gland myoepitheliomas, as well as a subset of malignant peripheral nerve sheath tumors, paragangliomas, carcinoids and astrocytomas. • In this study, none of the 25 epithelial tumors (including 8 breast carcinomas) labeled for Sox10. Nonaka D, et al. Am J Surg Pathol. 2008;32:1291‐1298. Sox10 Immunohistochemistry: initial utility in neural‐crest derived tissues • Normal tissues that demonstrated Sox10+ labeling: – Schwann cells, melanocytes and the myoepithelial cells of the salivary glands, bronchial mucosa, and breast. • Neoplastic tissues that demonstrated Sox10+ labeling: – 97% of melanomas, 100% of schwannomas and neurofibromas, 100% of salivary gland myoepitheliomas, as well as a subset of malignant peripheral nerve sheath tumors, paragangliomas, carcinoids and astrocytomas. • In this study, none of the 25 epithelial tumors (including 8 breast carcinomas) labeled for Sox10. Nonaka D, et al. Am J Surg Pathol. 2008;32:1291‐1298. Sox10 Immunohistochemistry: initial utility in neural‐crest derived tissues • Normal tissues that demonstrated Sox10+ labeling: – Schwann cells, melanocytes and the myoepithelial cells of the salivary glands, bronchial mucosa, and breast. • Neoplastic tissues that demonstrated Sox10+ labeling: – 97% of melanomas, 100% of schwannomas and neurofibromas, 100% of salivary gland myoepitheliomas, as well as a subset of malignant peripheral nerve sheath tumors, paragangliomas, carcinoids and astrocytomas. • In this study, none of the 25 epithelial tumors (including 8 breast carcinomas) labeled for Sox10. Nonaka D, et al. Am J Surg Pathol. 2008;32:1291‐1298. Melanocytes: Sox10+ Melanoma: Sox10+ Peripheral nerve Schwann cells: Sox10+ Nerve sheath‐derived granular cell tumor: Sox10+ Breast lobule: myoepithelial and luminal cells Sox10+ Breast ductule: myoepithelial and luminal cells Sox10+ Sox10 labels a subset of breast carcinomas • We first reported Sox10 positivity in breast carcinomas: – Overall, 40% of primary invasive breast ductal carcinomas – Specifically 66% of all triple negative carcinomas • 69% of basal‐like triple negative carcinomas • 45% metaplastic carcinomas – In contrast, 5% of estrogen receptor (ER)‐positive or Her2‐positive carcinomas labeled for Sox10 – Focal labeling in ER‐negative ductal carcinoma in situ. Cimino‐Mathews A, et al. Hum Pathol. 2013;44:959‐965. Sox10 labels a subset of breast carcinomas • We reported Sox10 positivity in breast carcinomas: – Overall, 40% of primary invasive breast ductal carcinomas – Specifically 66% of all triple negative carcinomas • 69% of basal‐like triple negative carcinomas • 45% metaplastic carcinomas – In contrast, 5% of estrogen receptor (ER)‐positive or Her2‐positive carcinomas labeled for Sox10 – Focal labeling in ER‐negative ductal carcinoma in situ. Cimino‐Mathews A, et al. Hum Pathol. 2013;44:959‐965. Basal‐like triple negative breast carcinoma (ER‐/PR‐/Her2‐ and CK5/6+) Basal‐like triple negative breast carcinoma: Sox10+ Metaplastic Carcinoma: 45% are Sox10 positive ER+ Ductal Carcinoma: Sox10 negative Sox10 positivity in breast ductal carcinomas has been confirmed in subsequent studies • 12%‐17% breast carcinomas are Sox10+ in subsequent studies; if reported, the majority are ER negative or basal‐like in phenotype • Gene expression profiling data has also identified overlapping Sox10 gene signatures in breast basal‐like breast carcinoma and salivary adenoid cystic carcinoma Mohamed, et al. Appl Immunohistochem Mol Morphol. 2013;21:506‐51. Ivanov SV, et al. Br J Cancer. 2013;109:444‐451. Tacha, et al. Arch Pathol Lab Med. 2014. [Epub ahead of print]. Miettinen, et al. Am J Surg Pathol. 2015 Feb 25. [Epub ahead of print]. Sox10 positivity in breast ductal carcinomas has been confirmed in subsequent studies • 12%‐17% breast carcinomas are Sox10+ in subsequent studies; if reported, the majority are ER negative or basal‐like in phenotype • Gene expression profiling data has also identified overlapping Sox10 gene signatures in breast basal‐like carcinoma and salivary gland adenoid cystic carcinoma Mohamed, et al. Appl Immunohistochem Mol Morphol. 2013;21:506‐51. Ivanov SV, et al. Br J Cancer. 2013;109:444‐451. Tacha, et al. Arch Pathol Lab Med. 2014. [Epub ahead of print]. Miettinen, et al. Am J Surg Pathol. 2015 Feb 25. [Epub ahead of print]. What other epithelial neoplasms label for Sox10? *Asch‐Kendrick, et al. Mod Pathol. 2015.28(S2):14A. (USCAP 2015 Poster Wednesday 1pm) What other epithelial neoplasms label for Sox10? • Salivary gland neoplasms (adenoid cystic carcinoma, acinic cell carcinoma, epithelial‐myoepithelial carcinoma, myoepitheliomas, myoepithelial carcinoma, pleomorphic adenoma) • Breast adenoid cystic carcinoma* • Skin adnexal neoplasms (eccrine spiradenoma/ cylindroma) • Soft tissue myoepitheliomas and carcinomas • Rarely: – embryonal carcinoma (25%) – pulmonary small cell carcinoma (7%) – lung or head and neck squamous cell carcinoma (5%) – pulmonary adenocarcinoma (fetal type) (1%) – Miettinen, et al. Am J Surg Pathol. 2015 Feb 25. [Epub ahead of print]. *Asch‐Kendrick, et al. A broad survey of neural crest transcription factor Sox10 in benign and neoplastic tissues. Mod Pathol. 2015.28(S2):14A. (USCAP 2015 Poster Wednesday 1pm) What other epithelial neoplasms label for Sox10? • Salivary gland neoplasms (adenoid cystic carcinoma, acinic cell carcinoma, epithelial‐myoepithelial carcinoma, myoepitheliomas, myoepithelial carcinoma, pleomorphic adenoma) • Breast adenoid cystic carcinoma* • Skin adnexal neoplasms (eccrine spiradenoma/ cylindroma) • Soft tissue myoepitheliomas and carcinomas • Rarely: – embryonal carcinoma (25%) – pulmonary small cell carcinoma (7%) – lung or head and neck squamous cell carcinoma (5%) – pulmonary adenocarcinoma (fetal type) (1%) – Miettinen, et al.